Redeye updates its estimates and valuation following the Q1 2025 report from Safeture.
Redeye updates its estimates and valuation following Lifco releasing its Q1 2025 report.
Redeye remains confident on the long-term case despite a major air pocket in the first quarter.
Higher costs partially offset by lower net financials in Q1 Outgrowing the sector on cash earnings i...
Redeye retains its positive view of Vertiseit following a Q1 report where FX and a higher headcount ...
Redeye updates its Base Case and forecasts following Fortnox’s Q1 report, with sales and EBITDA – CA...
Limited estimate revisions Promising outlook for international expansion Maintain fair value range o...
Strong SATCOM sales, but surprising setback in terminal sales '25e-'26e sales down 8-9% on FX headwi...
Q1 NAV -1% vs. ABGSCe Safe Life continues to deliver solid growth Fair value range lowered to SEK 23...
Acuvi redovisade ökad nettoomsättning och EBIT i det första kvartalet.
Redeye updates its estimates ahead of Arise’s Q1 report, which is due on 29 April.
Redeye gives its preview on OssDsign’s Q1 2025 report, due on May 6.
Idag, fredag 25 april, offentliggjorde Enrad AB (”Enrad” eller ”Bolaget”) sin rapport för kv1 2025.
Redeye comments on Alligator's first quarter 2025, during which a rights issue of gross SEK150m was ...
Redeye provides a short comment on today's order announcement from Scandinavian ChemoTech, this is t...
Redeye returns with a more in-depth take on the Q1 report.
Sales -1% and adj. EBIT -18% vs. ABGSCe Operating cash flow significantly better than expected Likel...
Dynavox delivered a robust Q1, with sales coming in 16% above our forecast and 13% ahead of consensu...
Redeye provides an initial comment on Safeture’s Q1 2025 report, which showed ARR growth slightly sh...
